Can Post-Mastectomy Radiation Therapy Be Omitted in T1-2 Clinically Node-Negative Breast Cancer Patients With a Positive Sentinel Lymph Node Biopsy?

Abstract

Background/Objective: The AMAROS trial demonstrated that both axillary radiation and axillary lymph node dissection (ALND) provide excellent locoregional control in patients with clinically node-negative T1-2 breast cancers and a positive sentinel lymph node biopsy (+SLNB). In that study, 18% of patients underwent total mastectomy (TM). We evaluate survival outcome of TM patients who do not require additional axillary treatment after identification of a +SLNB.